Real-world Efficacy of Erenumab on Migraine-associated Symptoms and Patient-reported Satisfaction Levels: A Retrospective Study in Japan-Reference-Cited by-同舟云学术

Real-world Efficacy of Erenumab on Migraine-associated Symptoms and Patient-reported Satisfaction Levels: A Retrospective Study in Japan

Published:2024 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Ihara Keiko¹²,Takahashi Nobuyuki¹,Ohtani Seiya¹³,Watanabe Narumi¹,Ishizuchi Kei¹,Takemura Ryo⁴,Tokuyasu Daiki¹,Sekiguchi Koji¹,Miyazaki Naoki⁴,Imai Shungo³,Hori Satoko³,Nakahara Jin¹,Takizawa Tsubasa¹

Affiliation:

1. Department of Neurology, Keio University School of Medicine, Japan

2. Japanese Red Cross Ashikaga Hospital, Japan

3. Division of Drug Informatics, Keio University Faculty of Pharmacy, Japan

4. Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_4037-24/_pdf

Reference30 articles.

1. 1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Prevalence, Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, Lancet, 2017. 390 (1990-2016): a systematic analysis for the Global Burden of Disease Study. 1211-1259, 2016.

2. 2. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17: 954-976, 2018.

3. 3. Sakai F, Igarashi H. Prevalence of Migraine in Japan: A Nationwide Survey. Cephalalgia 17: 15-22, 1997.

4. 4. Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15: 382-390, 2016.

5. 5. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16: 425-434, 2017.